Skip to content
Screener

Design Therapeutics, Inc. DSGN Other Income (Expense)

Other Income (Expense) at other companies

ALN
Alnylam PharmaceuticalsALNY
-$53.64M-180%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$6.13M-29.9%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$8.16M-39.8%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$4.42M-36.9%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$18K+5.9%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$710K+650%

Other financials

Income statement

See full
Revenue-
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$875.52M+227%
Enterprise value$865.48M+245%

Profitability

See full
Operating margin-3,685.8%
Net margin-3,663.7%

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0.0×
Current ratio22.3×-6.1×

Where this comes from

Reported directly by Design Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Design Therapeutics, Inc.’s 10-Q, filed November 7, 2024.

Filed
Nov 7, 2024
Fiscal quarter
Q3 FY2024
Calendar quarter
Q3 2024
Accession
0000950170-24-123349
Line itemThree Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023
Research and development (including related party amounts of $224, $247, $670 and $764, respectively)$11,876$13,257$32,193$46,051
General and administrative (including related party amounts of $134, $132, $405 and $402, respectively)4,3705,56513,49617,018
Total operating expenses16,24618,82245,68963,069
Loss from operations(16,246)(18,822)(45,689)(63,069)
Other income, net3,2073,0339,7528,049
Net loss$(13,039)$(15,789)$(35,937)$(55,020)
Net loss per share, basic and diluted$(0.23)$(0.28)$(0.64)$(0.98)
Weighted-average shares of common stock outstanding, basic and diluted56,620,73155,988,69156,555,31255,948,867

Item 1. Financial Statements.

FAQ

What is Design Therapeutics, Inc.'s other income (expense)?
Design Therapeutics, Inc. (DSGN) reported other income (expense) of $3.21M in Q3 2024.
How has Design Therapeutics, Inc.'s other income (expense) changed year-over-year?
Design Therapeutics, Inc.'s other income (expense) increased by 5.7% year-over-year, from $3.03M to $3.21M.
What is the long-term trend for Design Therapeutics, Inc.'s other income (expense)?
Over 2 years (2021 to 2023), Design Therapeutics, Inc.'s other income (expense) has grown at a 516.6% compound annual growth rate (CAGR), from $298K to $11.33M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Design Therapeutics, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude